Alvarez Ralph 4

What Happened

• Ralph Alvarez, a director of Eli Lilly & Co. (LLY), was granted/received 12.566 shares as an award on 2026-05-18. The filing reports a per‑share value of $988.09, for a total reported value of $12,416. This transaction is coded as an award/grant (A) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-19 (timely filing).
• Price/value: $988.09 per share; total reported value $12,416.
• Shares acquired: 12.566 (reported as fractional shares/stock units).
• Shares owned after transaction: not specified in the filing.
• Footnote F1: Shares were elected to be deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares upon the reporting person's separation from service.
• Footnote F2: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.

Context

• This was a deferred award under the directors' deferral plan (not an open‑market buy or a sale), so it reflects compensation deferral rather than an active investment decision. Deferred stock units will convert to actual shares when settled per plan terms.